NAD+ and Aesthetics: What It Does and What It Doesn’t

The pitch for NAD+ IV therapy usually goes something like this: your cells’ energy production slows with age, NAD+ is a key molecule in that process, declining NAD+ levels have been measured in aging tissue, therefore infusing NAD+ will reverse aging and improve your skin. The first three points in that chain are real. The fourth does not follow from them, and the aesthetic marketing around NAD+ has outrun the evidence considerably.

This is not a dismissal of NAD+ biology, which is genuinely interesting and actively researched. It is a request to separate what the science shows from what clinics are selling, because those are two different documents right now.

Jump to the FAQ section for specific questions about evaluating NAD+ clinic claims and the melasma research.

What NAD+ Actually Does in Your Cells: The Biology That Is Real

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell in the body. Its primary role is in energy metabolism: it carries electrons in the chemical reactions that produce ATP, the molecule cells use for energy. Without adequate NAD+, cells cannot perform this function efficiently.

It is also a substrate for several classes of enzymes involved in DNA repair and cellular stress responses. Sirtuins, a family of proteins associated with longevity research, require NAD+ to function. PARP enzymes, which respond to DNA damage, also consume NAD+ in significant quantities. When cells are under stress, whether from age, UV exposure, or metabolic demand, NAD+ gets used up faster than it is replenished.

Measured NAD+ levels do decline with age in human tissue. This is documented. Animal models, particularly rodent studies, have shown that raising NAD+ levels can improve markers of metabolism and cellular function. In mice, NAD+ precursor supplementation has reversed certain age-related declines. This is the scientific core that the aesthetic marketing cites, and it is genuinely interesting research.

The problem is the gap between “this works in mice” or “this improves biomarkers in humans” and “this will improve how your skin looks or ages.”

The Evidence Gap: What No Human Trial Has Shown About NAD+ Aesthetics

A PRISMA-guided systematic review examining NAD+ supplementation for anti-aging and wellness found that dermatologic and aesthetic aging outcomes were rarely studied in humans. The review identified no eligible human trials evaluating intravenous, intramuscular, or subcutaneous NAD+ specifically for skin aging or aesthetic outcomes. The available intervention data from human studies primarily contributed short-term safety information and biomarker data, meaning researchers confirmed that NAD+ levels rise after infusion. That is not the same as confirming a visible skin benefit.

This is the central issue. The claim chain in NAD+ marketing goes: aging reduces NAD+, therefore replenishing NAD+ reverses aging signs in skin. But step two of that chain has not been tested in humans at the level required to establish the claim. The mechanism is plausible. The clinical evidence is not there yet.

This matters particularly for the IV and IM delivery route that most aesthetic clinics offer. Oral NAD+ precursors (NMN, NR) have more human trial data, though still limited aesthetic-specific evidence. IV infusion is more expensive, more invasive, and in the specific context of skin and aesthetic outcomes, unsupported by published human trial data. For related context on evaluating evidence quality in the aesthetics space, the retatrutide and skin aesthetics article covers a similar framework for a different compound.

The One Narrower Application With Early Data: Topical NAD+ and Melasma

There is a specific, distinct application of NAD+ in aesthetics that should not be lumped in with the IV anti-aging marketing: topical NAD+ delivered via microneedling as a treatment for melasma. A published study on a topical NAD+ skinbooster combined with microneedling for melasma reported improvement in melasma severity scores over a treatment course, with a favorable safety profile and transient side effects (redness, swelling) resolving within approximately 48 hours.

This is worth knowing, but it needs to be clearly separated from the broader IV anti-aging market. Topical delivery via microneedling works through a completely different mechanism than IV infusion. The target (melasma, a specific pigmentation condition) is a defined, measurable outcome. The study design, with severity scores before and after, is appropriate for the claim being made. This is early research and should be treated as preliminary. But it is meaningfully different in evidence quality from “IV NAD+ reverses aging.”

If you are evaluating NAD+ microneedling specifically for melasma, that is a different conversation than evaluating IV NAD+ for general anti-aging. Do not let the marketing conflate them. The skin quality and intervention evidence article covers how to evaluate aesthetic treatment claims more broadly.

The Cost Reality: What You Are Paying For vs. What Is Proven

NAD+ IV therapy is expensive. Prices vary widely by market and clinic, but sessions commonly run several hundred to over a thousand dollars, and some clinics recommend a series of multiple sessions for “optimal results.” When the evidence base for aesthetic outcomes specifically is this thin, the cost reality deserves a direct sentence: this is a high-cost treatment with a currently weak aesthetic evidence base for the IV/IM route.

That does not make it fraudulent. Some patients report feeling better or having more energy during IV NAD+ courses, though separating that from placebo effect in a single-arm uncontrolled setting is difficult. Systemic wellness outcomes are a different conversation from skin aging outcomes. The issue is specifically with the marketing language around visible aesthetic results, which regularly makes claims the published literature does not support.

For comparison: retinoids, one of the most robustly evidence-supported topical interventions for skin aging, cost a fraction of a single NAD+ IV session. Evidence quality and cost do not correlate in the aesthetics market.

Red Flags in NAD+ Clinic Marketing

A few specific phrases signal that a clinic is overstating its evidence base. These apply to NAD+ marketing specifically, though they show up across the aesthetic supplement and IV therapy market.

“Cellular reset” or “cellular rejuvenation.” These are not clinical terms. They describe a desired outcome in language that sounds biological without making a testable claim. When you hear them, ask: what does “reset” mean specifically, and what trial data supports this outcome in humans?

“Detox.” NAD+ is not a detoxification agent in any established biochemical sense. Your liver and kidneys manage detoxification. This term in the context of NAD+ marketing is filler language with no clinical substance.

Promises of visible skin transformation without a specified timeframe or comparison. “You will look more youthful” with no timeframe, no before/after measurement, and no comparison group is not a clinical claim. It is a promise with no accountability structure.

Citing rodent studies or biomarker data to support visible aesthetic outcomes. “Studies show NAD+ restores youthful cell function” is technically supportable from rodent research and biomarker studies. It says nothing about your skin in six months. Ask specifically: is there human trial data showing visible skin improvement from this delivery method?

If You Are Currently Taking or Considering NAD+: What to Ask Your Provider

Frequently Asked Questions

Does NAD+ IV therapy actually improve skin aging?

There are no published human clinical trials showing that IV or IM NAD+ produces visible improvements in skin aging or aesthetic outcomes. NAD+ biology is well-established and the rationale is biologically plausible, but plausible mechanism is not the same as demonstrated effect. If a clinic is claiming visible skin results from IV NAD+, they are running ahead of the published evidence.

What is the difference between NAD+ for melasma vs. NAD+ for anti-aging?

They are essentially different treatments. Topical NAD+ delivered via microneedling for melasma is a specific, targeted application with early published data showing measurable improvement in melasma severity scores in human patients. IV NAD+ for general anti-aging is a systemic treatment with no published human trial data showing visible aesthetic benefit. The similarity is in the molecule. The delivery method, target indication, and evidence base are all different.

How should I evaluate whether an aesthetic clinic’s NAD+ claims are credible?

Ask for the specific published human trial data supporting the claimed outcome. Not rodent studies, not biomarker studies, not testimonials: human clinical trials with a defined before/after outcome measure and a comparison group. If the clinic cannot point to this for the specific claim they are making (visible skin improvement, anti-aging outcome), you are being asked to pay for a promise, not a demonstrated treatment. That may be your choice to make, but make it with accurate information.

This article is for educational purposes only and is not a substitute for professional medical advice. Always follow your injector’s or surgeon’s specific aftercare instructions.